NOVO-B:CPH
Novo Nordisk A/S
DKK 259.60
arrow_downward
-1.46%(-3.85) एक दिन
16 अक्टू॰, 5:00:00 pm GMT+2 · DKK
search
सभी चिह्न
| सिंबल | कीमत | बदलाव | प्रतिशत में बदलाव |
|---|
insights_autoNOVO-B के लिए सबसे अहम जानकारी जनरेट की जा रही है...
खोलें
DKK 261.00
सबसे ज़्यादा कीमत
DKK 262.15
सबसे कम कीमत
DKK 259.35
मार्केट कैपिटलाइज़ेशन
8.80 ख॰
औसत वॉल्यूम
52.26 लाख
वॉल्यूम
0.00
52 हफ़्तों में सबसे ज़्यादा कीमत
DKK 409.95
52 हफ़्तों में सबसे कम कीमत
DKK 224.25
बकाया शेयर
3.39 अ॰
कर्मचारियाें की संख्या
67 हज़ार
खोलें
DKK 261.00
सबसे ज़्यादा कीमत
DKK 262.15
सबसे कम कीमत
DKK 259.35
मार्केट कैपिटलाइज़ेशन
8.80 ख॰
औसत वॉल्यूम
52.26 लाख
वॉल्यूम
0.00
52 हफ़्तों में सबसे ज़्यादा कीमत
DKK 409.95
52 हफ़्तों में सबसे कम कीमत
DKK 224.25
बकाया शेयर
3.39 अ॰
कर्मचारियाें की संख्या
67 हज़ार
खबरें
वेब सोर्स और न्यूज़ पार्टनरों से मिली जानकारी
ad-hoc-news.de
·
23 मिनट पहले
Novo Nordisk updates denecimig review. What it means for Novo Nordisk stock
The Globe and Mail
·
1 घंटे पहले
Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?
Simply Wall Street
·
19 घंटे पहले
Novo Nordisk (NVO) Stock May Be Undervalued As Buybacks Continue
ad-hoc-news.de
·
1 दिन पहले
Novo-Nordisk stock heads into the next Xetra session at EUR 34.48
प्रोफ़ाइल
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Novo Nordisk A/S के बारे में
सीईओमाइक डाउस्टर
कर्मचारी66.7 हज़ार
स्थापना की तारीख1923
हेडक्वार्टरBagsværd, डेनमार्क राजधानी क्षेत्र, डेनमार्क
सेक्टर-
वेबसाइटnovonordisk.com